KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Thermo Fisher Scientific (TMO) EBIAT (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed EBIAT for 16 consecutive years, with $1.8 billion as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, EBIAT rose 8.81% year-over-year to $1.8 billion, compared with a TTM value of $6.3 billion through Dec 2024, up 5.24%, and an annual FY2025 reading of $6.7 billion, up 5.08% over the prior year.
  • EBIAT was $1.8 billion for Q4 2024 at Thermo Fisher Scientific, up from $1.6 billion in the prior quarter.
  • Across five years, EBIAT topped out at $2.5 billion in Q4 2020 and bottomed at $788.0 million in Q1 2020.
  • Average EBIAT over 5 years is $1.7 billion, with a median of $1.7 billion recorded in 2021.
  • The sharpest move saw EBIAT skyrocketed 196.57% in 2021, then plummeted 41.8% in 2023.
  • Year by year, EBIAT stood at $2.5 billion in 2020, then plummeted by 33.72% to $1.7 billion in 2021, then fell by 5.12% to $1.6 billion in 2022, then increased by 4.57% to $1.6 billion in 2023, then grew by 8.81% to $1.8 billion in 2024.
  • Business Quant data shows EBIAT for TMO at $1.8 billion in Q4 2024, $1.6 billion in Q3 2024, and $1.5 billion in Q2 2024.